Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention

doi:10.1016/0014-2999(94)90687-4

European Journal of Pharmacology

Volume 257, Issues 1–2, 12 May 1994, Pages 7-12

https://doi.org/10.1016/0014-2999(94)90687-4 Get rights and content

Abstract

The memory-enhancing potential of D-cycloserine (cycloserine) a partial agonist at the glycine recognition site on the NMDA receptor, was evaluated in mice using a thirst-motivated linear maze learning task. Immediate acute post-training injections (10, 20 and 80 mg/kg) significantly improved retention relative to vehicle-injected controls. Retention was also facilitated if cycloserine (3 and 10 mg/kg but not 20 or 40 mg/kg) was administered 20 min before the retention test. Acquisition of the habit was accelerated if cycloserine (3 mg/kg) was injected 20 min before the training session. Acute post-training injections failed to facilitate retention if mice were pretreated with cycloserine (3 mg/kg) b.i.d. for 15 days before training on the maze. These results indicate that acute cycloserine administration can enhance consolidation and retrieval of memory but that desensitization may occur with chronic exposure to the drug.

References (26)

J.F. Flood et al.
Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor
Eur. J. Pharmacol.
(1992)
V. Heale et al.
MK-801 and AP-5 impair acquisition but not retention, of the Morris milk maze
Pharmacol. Biochem. Behav.
(1990)
W.F. Hood et al.
D-Cycloserine: a ligand for the $N- methyl - D - aspartate$ coupled glycine receptor has partial agonist characteristics
Neurosci. Lett.
(1989)
S.J. Lei et al.
Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex
Neuron
(1992)
J.B. Monahan et al.
D-Cycloserin, a positive modulator of the $N- methyl- D - aspartate$ receptor enhances performance of learning tasks in rats
Pharmacol. Biochem. Behav.
(1989)
G.M. Schuster et al.
D-Cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task
Eur. J. Pharmacol.
(1992)
A.H. Tang et al.
Both competitive and non-competitive antagonists of $N- methyl- D - aspartic$ acid disrupt brightness discrimination in rats
Eur. J. Pharmacol.
(1988)
A. Antola et al.
Long term potentiation and NMDA receptors in rat visual cortex
Nature
(1987)
M. Benveniste et al.
A kinetic analysis of the modulation of $N- methyl - D - aspartic$ acid receptors by glycine in cultured mouse hippocampal neurones
J. Physiol. (London)
(1990)
G.L. Colinridge et al.
NMDA receptors - their role in long term potentiation
Trends Neurosci.
(1987)

G.M. Conzelman et al.

On the physiological disposition of cycloserine in experimental animals

Am. Rev. Tuberc. Pulmonary Dis.

(1956)

V.L. Dawson et al.

Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures

Grinwood, S., G.J.C. Wilde and A.C. Foster, Interactions between the glutamate and glycine recognition sites of the...

Cited by (168)

D-cycloserine augmentation of cognitive behavioral therapy for delusions: A randomized clinical trial
2020, Schizophrenia Research
D-cycloserine (DCS) promotes consolidation of extinction learning. This study extends earlier work by examining whether DCS can enhance cognitive behavioral therapy (CBT) for delusions.
Adults reporting moderate or greater delusions were randomly assigned to receive 50 mg of DCS or placebo prior to 10 weekly CBT sessions. The primary outcome was change in severity of delusions measured with the Psychotic Symptom Rating Scale delusion subscale (PSYRATS-D). Secondary outcomes included persistence of response at 3 and 6 month follow-up and the effects of DCS on memory consolidation and cognitive flexibility. Fifty-eight participants were randomized and 44 completed the trial.
The DCS and placebo groups did not differ in change from baseline to end of CBT on PSYRATS-D, nor did DCS improve memory consolidation or cognitive flexibility compared to placebo. However, at the 3 month follow-up visit (week 24), 47% of participants who completed treatment with DCS reported a 20% or greater decrease on PSYRATS-D compared to 15% in the placebo group (p = .04). Change in distress across CBT sessions interacted with treatment group to predict change from baseline to week 24 in PSYRATS-D total score (p = .03) such that response at week 24 was greatest in DCS-treated participants who experienced a decrease in distress during CBT sessions.
DCS augmentation of CBT did not improve delusions compared to placebo during treatment; however, DCS was associated with a higher response rate at 3-month follow-up. DCS may produce a delayed therapeutic effect, associated with successful CBT sessions, but this finding requires replication.
D-Cycloserine reverses scopolamine-induced object and place memory deficits in a spontaneous recognition paradigm in rats
2019, Pharmacology Biochemistry and Behavior
d-Cycloserine (DCS) is a partial agonist of the glutamatergic N-methyl-d-aspartate (NMDA) receptor-associated glycine site, and it prevents the amnesic effects of the muscarinic receptor antagonist scopolamine in various memory tests in rodents. In the present study, we tested the hypothesis that DCS has anti-amnesic effects in scopolamine-induced deficits using spontaneous object recognition and place recognition tests. In both tests, scopolamine (0.5 mg/kg, i.p.) was systemically administered 60 min prior to testing, while DCS (7.5, 15, 30 mg/kg, i.p.) was administered 30 min before testing, which consisted of a sample phase (5 min), a delay interval (15 min) and a test phase (2 min). DCS treatment reversed scopolamine-induced deficits in discriminatory behavior during the test phase. However, DCS did not affect decreased object exploration itself or increased thigmotaxis in the open-field arena induced by scopolamine. These results support our hypothesis and suggest differential contributions of glutamatergic-cholinergic system interactions to recognition memory and non-mnemonic exploratory behaviors.
The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders
2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Cognitive dysfunction is a principal determinant of functional impairment in major depressive disorder (MDD) and often persists during periods of euthymia. Abnormalities in the glutamate system, particularly in N-methyl-d-aspartate receptors (NMDARs) activity, have been shown to contribute to both mood and cognitive symptoms in MDD. The current narrative review aims to evaluate the potential pro-cognitive effects of targeting the glycine site of NMDARs in the treatment of psychiatric disorders, with a special focus on how these results may apply to MDD. Literature databases were searched from inception to May 2018 for relevant pre-clinical and clinical studies evaluating antidepressant and pro-cognitive effects of NMDAR glycine site modulators in both MDD and non-MDD samples. Six glycine site modulators with pro-cognitive and antidepressant properties were identified: d-serine (co-agonist), d-cycloserine (partial agonist), d-alanine (co-agonist), glycine (agonist), sarcosine (co-agonist) and rapastinel (partial agonist). Preclinical animal studies demonstrated improved neuroplasticity and pro-cognitive effects with these agents. Numerous proof-of-concept clinical trials demonstrated pro-cognitive and antidepressant effects trans-diagnostically (e.g., in healthy participants, MDD, schizophrenia, anxiety disorders, major neurocognitive disorders). The generalizability of these clinical studies was limited by the small sample sizes and the paucity of studies directly evaluating cognitive effects in MDD samples, as most clinical trials were in non-MDD samples. Taken together, preliminary results suggest that the glycine site of NMDARs is a promising target to ameliorate symptoms of depression and cognitive dysfunction. Additional rigorously designed clinical studies are required to determine the cognitive effects of these agents in MDD.
The Role of Serine Racemase in the Pathophysiology of Brain Disorders
2018, Advances in Pharmacology
The N-methyl-d-aspartate receptor (NMDAR) is unique in requiring two agonists to bind simultaneously to open its cation channel: the neurotransmitter, glutamate, and the coagonists, glycine, or d-serine. The Snyder laboratory was the first to clone serine racemase (SR), the enzyme that synthesizes d-serine, and to localize it immunocytochemically. Our laboratory has focused on the role of d-serine in brain disorders. Silencing the expression of SR, a risk gene for schizophrenia (SCZ), in mice (SR −/−), results in a phenotype that closely resembles SCZ including: cortical atrophy, reduced dendritic spine density and complexity, downregulation of parvalbumin-positive cortical GABAergic neurons, and cognitive impairments. This pathology can be reversed by treatment of SR −/− mice with d-serine in adulthood. SR −/− mice also exhibit abnormal response toward abusable substances, such as stimulants. They show reduced behavioral sensitization to d-amphetamine, but fail to extinguish it. Place preference to cocaine is altered, and the hedonic response to it is profoundly impaired as assessed by intracranial self-stimulation. d-cycloserine, a partial agonist at the NMDAR glycine modulatory site, shows therapeutic benefit for treating pathologic anxiety in combination with behavioral therapies. Studies in vitro with cortical culture and in vivo with middle cerebral artery occlusion show that silencing SR provides substantial protection against ischemic neuronal death. Finally, the switch of SR expression from neurons to reactive astrocytes after closed head trauma accounts for the reduced in vivo neuroplasticity, electroencephalogram abnormalities, and cognitive impairments.
Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions
2016, Biological Psychiatry
Advances in the understanding of the neurobiology of fear extinction have resulted in the development of d-cycloserine (DCS), a partial glutamatergic N-methyl-D-aspartate agonist, as an augmentation strategy for exposure treatment. We review a decade of research that has focused on the efficacy of DCS for augmenting the mechanisms (e.g., fear extinction) and outcome of exposure treatment across the anxiety disorders. Following a series of small-scale studies offering strong support for this clinical application, more recent larger-scale studies have yielded mixed results, with some showing weak or no effects. We discuss possible explanations for the mixed findings, pointing to both patient and session (i.e., learning experiences) characteristics as possible moderators of efficacy, and offer directions for future research in this area. We also review recent studies that have aimed to extend the work on DCS augmentation of exposure therapy for the anxiety disorders to DCS enhancement of learning-based interventions for addiction, anorexia nervosa, schizophrenia, and depression. Here, we attend to both DCS effects on facilitating therapeutic outcomes and additional therapeutic mechanisms beyond fear extinction (e.g., appetitive extinction, hippocampal-dependent learning).
The Therapeutic Role of d-Cycloserine in Schizophrenia
2016, Advances in Pharmacology
The ketamine model for schizophrenia has led to several therapeutic strategies for enhancing N-methyl d-aspartate (NMDA) receptor activity, including agonists directed at the glycine receptor site and inhibitors of glycine reuptake. Because ketamine may primarily block NMDA receptors on inhibitory interneurons, drugs that reduce glutamate release have also been investigated as a means of countering a deficit in inhibitory input. These approaches have met with some success for the treatment of negative and positive symptoms, but results have not been consistent. An emerging approach with the NMDA partial agonist, d-cycloserine (DCS), aims to enhance plasticity by intermittent treatment. Early trials have demonstrated benefit with intermittent DCS dosing for negative symptoms and memory. When combined with cognitive remediation, intermittent DCS treatment enhanced learning on a practiced auditory discrimination task and when added to cognitive behavioral therapy, DCS improved delusional severity in subjects who received DCS with the first CBT session. These studies require replication, but point toward a promising strategy for the treatment of schizophrenia and other disorders of plasticity.

View all citing articles on Scopus

View full text

Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention

Abstract

Eur. J. Pharmacol.

Pharmacol. Biochem. Behav.

Neurosci. Lett.

Neuron

Pharmacol. Biochem. Behav.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Long term potentiation and NMDA receptors in rat visual cortex

Nature

A kinetic analysis of the modulation of N-methyl-D-aspartic acid receptors by glycine in cultured mouse hippocampal neurones

J. Physiol. (London)

NMDA receptors - their role in long term potentiation

Trends Neurosci.

On the physiological disposition of cycloserine in experimental animals

Am. Rev. Tuberc. Pulmonary Dis.

Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures

A kinetic analysis of the modulation of $N- methyl - D - aspartic$ acid receptors by glycine in cultured mouse hippocampal neurones